Mutant IDH1/IDH2 Inhibitor Compounds for 2HG-Driven Cancer
Solution Overview
Problem
Mutant IDH1 and IDH2 enzymes in certain cancer cells exhibit a new ability to catalyze the NAPH-dependent reduction of α-ketoglutarate to R(−)-2-hydroxyglutarate, contributing to cancer formation and progression, necessitating the development of inhibitors to target these enzymes for therapeutic treatment.
Innovation Solution
Development of compounds of Formula I, or their pharmaceutically acceptable salts, which inhibit mutant IDH1 and/or IDH2 enzymes, specifically designed to target their alpha hydroxyl neoactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mutant IDH1 and IDH2 enzymes catalyze the reduction of α-ketoglutarate to R(−)-2-hydroxyglutarate, then cancer formation and progression are promoted, but inhibiting this enzymatic activity requires development of specific inhibitor compounds
Solution Approach 1:
The patent applies parameter changes by modifying chemical structures of inhibitor compounds (Formula I, Ia, Ib, B, C, Ic, Id, Ie, If, Ig, II, III, IIIa, IIIb, IIIc, and IIId) to optimize their ability to inhibit mutant IDH1 and IDH2 enzymes. By systematically varying molecular parameters such as substituent groups, ring structures, and stereochemistry, the invention achieves effective inhibition of the neoactivity while managing structural complexity through rational drug design
Solution Approach 2:
The patent employs intermediary compounds that specifically bind to the mutant IDH1 and IDH2 enzymes to block their neoactivity. These inhibitor compounds act as intermediaries between the therapeutic goal (inhibiting cancer-promoting enzymatic activity) and the target enzyme, providing selective inhibition without requiring direct modification of the enzyme itself
2Measurement precision
If specific inhibitors are developed to target mutant IDH1 and IDH2 neoactivity, then cancer treatment specificity is improved, but the scope of applicable compounds is limited
Solution Approach 1:
The patent achieves universality by developing a series of inhibitor compounds with a common core structure (Formula I) that can inhibit both mutant IDH1 and mutant IDH2 enzymes. The versatile scaffold allows the same basic compound type to target multiple mutant forms across different cancer types, while specific substituents can be adjusted to fine-tune specificity for particular clinical indications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit mutant IDH1 and IDH2 enzymes, providing a potential therapeutic approach for treating cancers characterized by these enzymes.
Implementation Method 1
mutations of IDH1 present in certain cancer cells result in a new ability of the enzyme to catalyze the NAPH-dependent reduction of α-ketoglutarate to R(−)-2-hydroxyglutarate (2HG)
Implementation Method 2
catalyze the NAPH-dependent reduction of α-ketoglutarate to R(−)-2-hydroxyglutarate (2HG)
Data Source
AI summary
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.